NCT00025506View on ClinicalTrials.gov

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Recurrent Uterine Corpus SarcomaUterine Carcinosarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Thalidomide

Given orally

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00025506 - Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | Biotech Hunter | Biotech Hunter